Molecular Pharmacology (USA), Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MLPH research report →
Companymolpharm.aspetjournals.org
Molecular Pharmacology (USA) Limited, a development stage company, develops and commercializes pain and inflammation management products primarily in Australia and the United States. The company, through its subsidiary, Molecular Pharmacology Pty. Ltd.
- CEO
- Jeffrey David Edwards
- IPO
- 2009
- Employees
- 1
- HQ
- Perth, WA, AU
Price Chart
Valuation
- Market Cap
- $111.55K
- P/E
- -832.96
- P/S
- 0.00
- P/B
- 0.00
- EV/EBITDA
- -92.96
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.00%
- ROIC
- 0.00%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-5,520 · 99.39%
- EPS
- $0.00 · 100.00%
- Op Income
- $-5,520
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $0.01
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -0.49
- Avg Volume
- 11.08K
Get TickerSpark's AI analysis on MLPH
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our MLPH Coverage
We haven't published any research on MLPH yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate MLPH Report →